
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Vascular Biogenics Ltd | NASDAQ:VBLT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.156 | 0.1598 | 0.1599 | 0 | 00:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in charter)
Not Applicable | ||||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices) | (Zip Code) |
Registrant’s
telephone number, including area code:
N/A
(Former name or former address, if changed since last report)
Securities registered or to be registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) |
Name of each exchange on which registered | ||
The
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
At the Special Meeting of Shareholders of Notable Labs, Ltd. (the “Company”) held on March 22, 2024, a quorum being present, the shareholders of the Company:
(i) | approved the Company’s Employee Share Ownership and Option Plan (2024); | |
(ii) | approved the amendment of the compensation terms and agreement of Thomas A. Bock, the Company’s Chief Executive Officer; | |
(iii) | approved the appointment of WithumSmith+Brown, PC, as the Company’s independent registered public accounting firm for the year ended December 31, 2023; and | |
(iv) | approved a compensation policy for the Directors and Officers of the Company. |
1. The votes cast by shareholders with respect to the approval of the Company’s Employee Share Ownership and Option Plan (2024), were as follows:
Votes “For” | Votes “Against” | Abstentions | ||
3,912,853 | 83,558 | 15,798 |
There were no broker non-votes with respect to this proposal.
2. The votes cast by shareholders with respect to the approval of the amendment of the compensation terms and agreement of Thomas A. Bock, the Company’s Chief Executive Officer, were as follows:
Votes “For” | Votes “Against” | Abstentions | ||
3,904,346 | 91,003 | 16,861 |
There were no broker non-votes with respect to this proposal.
3. The votes cast by shareholders with respect to approval of the appointment of WithumSmith+Brown, PC, as the Company’s independent registered public accounting firm for the year ended December 31, 2023, were as follows:
Votes “For” | Votes “Against” | Abstentions | ||
3,996,504 | 14,337 | 1,368 |
There were no broker non-votes with respect to this proposal.
4. The votes cast by shareholders with respect to the approval of a compensation policy for the Directors and Officers of the Company, were as follows:
Votes “For” | Votes “Against” | Abstentions | ||
3,878,055 | 114,978 | 19,176 |
There were no broker non-votes with respect to this proposal.
The affirmative votes cast with respect to Items 1, 2 and 4 above also included a majority of the shares held by non-controlling shareholders or shareholders without a personal interest in the proposal voted at the meeting, excluding abstentions, as required under the Israeli Companies Law, 5759-1999.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NOTABLE LABS, LTD. | |||
Date: | March 25, 2024 | By: | /s/ Thomas A. Bock |
Name: | Thomas A. Bock | ||
Title: | Chief Executive Officer |
Cover |
Mar. 22, 2024 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Mar. 22, 2024 |
Entity File Number | 001-36581 |
Entity Registrant Name | NOTABLE LABS, LTD. |
Entity Central Index Key | 0001603207 |
Entity Incorporation, State or Country Code | L3 |
Entity Address, Address Line One | 320 Hatch Drive |
Entity Address, City or Town | Foster City |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 94404 |
City Area Code | (415) |
Local Phone Number | 851-2410 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Ordinary Shares, par value NIS 0.35 each |
Trading Symbol | NTBL |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
1 Year Vascular Biogenics Chart |
1 Month Vascular Biogenics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions